PILLS Act
- Bill Number
- S. 1891
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Taxation
- Status
- Introduced
- Latest Action
- 2025-05-22: Read twice and referred to the Committee on Finance.
- Last Updated
- 2025-12-05T22:51:48Z
AI-Generated Summary
Purpose
The PILLS Act (S. 1891) aims to encourage domestic production of generic drugs and biosimilars—affordable alternatives to brand-name medications—by providing tax incentives. This addresses supply chain vulnerabilities, particularly reliance on foreign manufacturing, to ensure a stable, U.S.-based supply of essential medicines.
Key Provisions
- Generic Drugs and Biosimilars Production Credit (Section 45BB):
- Offers a tax credit equal to 30% of the "value added" (gross receipts from sales minus costs of purchased components) for eligible components produced and sold in the U.S. to unrelated parties.
- Increases to 35% for final production stages of drug substances, drug products, or biological products.
- Adds a "domestic content bonus" of up to 20% based on the percentage of U.S.-sourced materials in components, requiring documentation and certifications.
- Applies to production after enactment, but phases out starting in 2031 (75% in 2031, 50% in 2032, 25% in 2033, and 0% after 2033).
- Eligible components include approved generic drugs, licensed biosimilars, and related materials (e.g., raw ingredients, packaging, testing services) used in their production.
- Excludes credits for production by "foreign entities of concern" (e.g., certain Chinese or Russian firms) or at facilities with unresolved FDA warning letters issued since 2009.
- Production must occur entirely in the U.S., covering all manufacturing steps like synthesis, packaging, and testing.
- Generic Drugs and Biosimilars Investment Credit (Section 48F):
- Provides a 25% tax credit on the basis (cost) of qualified property (e.g., equipment, buildings) placed in service as part of a U.S.-based facility primarily for producing eligible components.
- Qualified facilities must be owned by the taxpayer and located in the U.S. or its territories; excludes office or administrative spaces.
- Applies to property placed in service after December 31, 2026, but ends for construction beginning after December 31, 2028.
- Eligible taxpayers cannot be foreign entities of concern.
- Additional Features for Both Credits:
- Allows "elective payment" (direct cash refund from the IRS instead of offsetting taxes) for certain entities, including nonprofits or governments, starting after December 31, 2024.
- Permits transfer of credits to unrelated parties for cash, enhancing flexibility for smaller producers.
- IRS to issue regulations for implementation, including record-keeping and certifications.
Significant Changes to Existing Law
- Adds new sections (45BB and 48F) to the Internal Revenue Code (IRC), integrating these credits into the general business credit framework (Section 38) and investment credit rules (Section 46).
- Expands elective payment (Section 6417) and credit transferability (Section 6418) provisions to include these new credits, allowing broader access beyond traditional corporate taxpayers.
- Introduces phase-out mechanisms and domestic content requirements not previously tied to pharmaceutical production credits.
- Coordinates with existing credits (e.g., excludes overlap with clean energy investment credits under Section 48F or rehabilitation credits under Section 47) to prevent double-dipping.
Potential Impacts
- On Government Agencies: Increases IRS administrative burden for verifying domestic content, FDA compliance, and credit claims; may reduce federal tax revenue short-term (offset by long-term supply chain benefits). Enhances FDA's role in disqualifying non-compliant facilities.
- On Citizens: Could lower generic drug and biosimilar prices by boosting U.S. production, improving access to affordable medications and reducing shortages. Promotes public health security by diversifying supply away from foreign dependencies.
- On International Relations: Discourages reliance on adversarial nations (via foreign entity exclusions), potentially straining trade ties but strengthening U.S. economic independence in pharmaceuticals.
- Broader Economy: Stimulates job creation in manufacturing and related sectors; encourages investment in U.S. facilities, with credits expiring to transition to market-driven production.
Main Stakeholders Affected
- Pharmaceutical Manufacturers: Generic and biosimilar producers (e.g., companies like Teva or Amgen) benefit most from credits, especially smaller or startup firms via transfers and payments; brand-name drug makers may face indirect competition.
- Investors and Taxpayers: Eligible U.S.-based firms gain tax relief; ineligible foreign-linked entities lose out.
- Consumers and Healthcare Providers: Gain from potential cost reductions and reliable supply.
- Government Entities: IRS (enforcement), FDA (compliance checks), and Congress (fiscal oversight).
- Supply Chain Partners: Suppliers of U.S.-made materials (e.g., raw chemical producers) see boosted demand from domestic content rules.
Notable Legal, Constitutional, or Political Implications
- Legal: Relies on Treasury/IRS regulatory authority for implementation, potentially leading to disputes over definitions (e.g., "value added" calculations) or certifications. Ensures compliance with FDA standards without altering drug approval processes under the Federal Food, Drug, and Cosmetic Act or Public Health Service Act.
- Constitutional: No apparent conflicts; tax incentives are a standard congressional power under Article I, Section 8. Exclusions for foreign entities align with national security precedents but could invite challenges under trade agreements like USMCA.
- Political: Advances "Buy American" policies for critical goods, appealing to bipartisan concerns over drug shortages (e.g., post-COVID vulnerabilities). May spark debate on fiscal costs (estimated revenue loss) versus benefits in reducing import dependencies, with phase-outs promoting sustainability.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Recent Actions
- 2025-05-22: Read twice and referred to the Committee on Finance.
- 2025-05-22: Introduced in Senate
Bill Versions
- Producing Incentives for Long-term production of Lifesaving Supply of medicine Act — issued 2025-05-22 — PDF (18 pages)